FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Immunomedics, Inc. patents


      
Recent patent applications related to Immunomedics, Inc.. Immunomedics, Inc. is listed as an Agent/Assignee. Note: Immunomedics, Inc. may have other listings under different names/spellings. We're not affiliated with Immunomedics, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics, Inc.-related inventors



Search recent Press Releases: Immunomedics, Inc.-related press releases
Count Application # Date Immunomedics, Inc. patents (updated weekly) - BOOKMARK this page
12014028686009/25/14Immunoconjugates with an intracellularly-cleavable linkage
22014028686109/25/14Rs7 antibodies
32014023420908/21/14Chimeric and humanized anti-histone antibodies
42014022717808/14/14Humanized anti-hla-dr antibodies
52014022717908/14/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
62014022718008/14/14Antibody-sn-38 immunoconjugates with a cl2a linker
72014022854108/14/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
82014021991408/07/14Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
92014021995608/07/14Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
102014021242507/31/14Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
112014019335907/10/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
122014017829406/26/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
132014017006506/19/14Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
142014015427306/05/14Anthracycline-antibody conjugates for cancer therapy
152014014738205/29/14Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
162014014092405/22/14Humanized l243 antibodies
172014014092405/22/14Humanized l243 antibodies
182014012003505/01/14Rs7 antibodies
192014012003505/01/14Rs7 antibodies
202014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
212014011286504/24/14Anti-cd19 antibodies
222014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
232014011286504/24/14Anti-cd19 antibodies
242014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
252014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
262014009925804/10/14Camptothecin-binding moiety conjugates
272014009925804/10/14Camptothecin-binding moiety conjugates
282014009925804/10/14Camptothecin-binding moiety conjugates
292014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
302014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
312014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
322014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
332014007962903/20/14Class i anti-cea antibodies and uses thereof
342014007962903/20/14Class i anti-cea antibodies and uses thereof
352014005806702/27/14Immunoconjugates with an intracellularly-cleavable linkage
362014004463902/13/14Antibody therapy
372014004464002/13/14Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
382014003754302/06/14Anti-pancreatic cancer antibodies
392014003826102/06/14Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
402014003828402/06/14Mammalian cell lines for increasing longevity and protein yield from a cell culture
412014001716801/16/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
422014001719701/16/14Anti-cd19 antibodies
432014000407801/02/14Immunoconjugates with an intracellularly-cleavable linkage
442013031582111/28/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
452013030917711/21/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
462013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
472013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
482013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
492013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
502013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
512013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
522013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
532013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
542013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
552013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
562013017106407/04/13Anti-cd74 immunoconjugates and methods of use
572013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
582013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
592013017106407/04/13Anti-cd74 immunoconjugates and methods of use
602013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
612013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
622013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
632013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
642013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
652013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
662013015669106/20/13Antibody therapy
672013015669106/20/13Antibody therapy
682013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
692013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
702013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
712013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
722013012191305/16/13Anti-cd19 antibodies
732013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
742013012191305/16/13Anti-cd19 antibodies
752013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
762013009503404/18/13Anti-cd74 immunoconjugates and methods
772013009045804/11/13Immunoconjugates with an intracellularly-cleavable linkage
782013007818203/28/13Structural variants of antibodies for improved therapeutic characteristics
792013007826303/28/13Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
802013007132003/21/13Immunotherapy of autoimmune disorders using antibodies which target b-cells
812013007140603/21/13Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
822013007265903/21/13Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
832013003986102/14/13Dye conjugated peptides for fluorescent imaging
842013003449202/07/13Class i anti-cea antibodies and uses thereof
852012032856412/27/12Camptothecin-binding moiety conjugates
862012032863412/27/12Immunoconjugates with an intracellularly-cleavable linkage
872012032155312/20/12Ultrafiltration concentration of allotype selected antibodies for small-volume administration
882012028217811/08/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
892012027610011/01/12Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
902012023095309/13/12Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
912012021496908/23/12Methods and compositions for f-18 labeling of proteins, peptides and other molecules
922012019632608/02/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
932012018954207/26/12Anti-cd19 antibodies
942012018347207/19/12Immunotherapy of b-cell malignancies using anti-cd22 antibodies
952012018355007/19/12Therapeutic using a bispecific antibody
962012014908506/14/12Fusion proteins containing recombinant cytotoxic rnases
972012014137206/07/12Rs7 antibodies
982012014137506/07/12Anti-mucin antibodies for early detection and treatment of pancreatic cancer
992012013492005/31/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1002012011455605/10/12Immunotherapy of autoimmune disorders using antibodies which target b-cells
1012012010723505/03/12Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1022012008829904/12/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
1032012008261704/05/12Immunoconjugates with an intracellularly-cleavable linkage
1042012007672703/29/12In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1052012006399303/15/12Therapeutic and diagnostic conjugates for use with multispecific antibodies
1062012003979702/16/12Antibody therapy
1072012004043102/16/12Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1082012003418502/09/12Anti-cd20 antibodies and fusion proteins therof and methods of use
1092011031153112/22/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
1102011030563112/15/11Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1112011030006612/08/11Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
1122011029351312/01/11Immunoconjugates with an intracellularly-cleavable linkage
1132011028691811/24/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
1142011028080111/17/11Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1152011027470411/10/11Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1162011025605310/20/11Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1172011024384110/06/11Antibody-based depletion of antigen-presenting cells and dendritic cells
1182011024454610/06/11Internalizing anti-cd74 antibodies and methods of use
1192011023630409/29/11Structural variants of antibodies for improved therapeutic characteristics
1202011023640409/29/11Methods for protein expression in mammalian cells in serum-free medium
1212011022940709/22/11Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1222011022364509/15/11Multivalent carriers of bi-specific antibodies
1232011019502308/11/11Internalizing anti-cd74 antibodies and methods of use
1242011018908508/04/11Antibody therapy
1252011018926808/04/11Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1262011017112607/14/11Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1272011016507207/07/11Detection of early-stage pancreatic adenocarcinoma
1282011016507307/07/11Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1292011011701005/19/11Methods and compositions for administering therapeutic and diagnostic agents
1302011011710505/19/11Method of treating immune disease using b-cell antibodies
1312011011085405/12/11Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1322011007623303/31/11Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1332011007015503/24/11Anti-cd74 immunoconjugates and methods
1342011007015603/24/11Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1352011006465303/17/11Class i anti-cea antibodies and uses thereof
1362011005248903/03/11Anti-cd19 antibodies
1372010031116212/09/10Mammalian cell lines for increasing longevity and protein yield from a cell culture
1382010028490611/11/10Internalizing anti-cd74 antibodies and methods of use
1392010027263610/28/10Anti-cd74 immunoconjugates and methods of use
1402010026649610/21/10Anti-cd74 immunoconjugates and methods of use
1412010026649710/21/10Internalizing anti-cd74 antibodies and methods of use
1422010023377909/16/10Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1432010022688409/09/10Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1442010022117509/02/10Antibody therapy
1452010022117709/02/10Rs7 antibodies
1462010021666208/26/10Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1472010020296108/12/10D-amino acid peptides
1482010019626608/05/10Humanized anti-hla-dr antibodies
1492010019626708/05/10Humanized l243 antibodies
1502010019698908/05/10Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1512010018964107/29/10Novel strategies for improved cancer vaccines
1522010015880206/24/10Chimeric, human and humanized anti-csap monoclonal antibodies
1532010015880306/24/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1542010013662606/03/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1552010010458904/29/10Immunoconjugates with an intracellularly-cleavable linkage
1562010007484003/25/10Anthracycline-antibody conjugates for cancer therapy
1572010006813603/18/10Anti-cd19 antibodies
1582010004054102/18/10Structural variants of antibodies for improved therapeutic characteristics
1592010003473802/11/10Structural variants of antibodies for improved therapeutic characteristics
1602010001504601/21/10Camptothecin-binding moiety conjugates
1612010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1622010000885501/14/10Production and use of novel peptide-based agents with bispecific antibodies
1632010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1642009030458012/10/09Anti-pancreatic cancer antibodies
1652009029903312/03/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1662009029109311/26/09Immunoconjugates with an intracellularly-cleavable linkage
1672009028575211/19/09Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1682009027464911/05/09Bispecific antibody point mutations for enhancing rate of clearance
1692009025273110/08/09Multivalent carriers of bi-specific antibodies
1702009025317910/08/09Mammalian cell lines for increasing longevity and protein yield from a cell culture
1712009024613010/01/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1722009024613110/01/09Production and use of novel peptide-based agents for use with bi-specific antibodies
1732009024621410/01/09Fusion proteins containing recombinant cytotoxic rnases
1742009023875709/24/09Methods and compositions for administering therapeutic and diagnostic agents
1752009024003709/24/09Humanized antibodies and methods of humanizing antibodies
1762009018597407/23/09Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1772009015516606/18/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1782009015525306/18/09Anti-cd20 antibodies and fusion proteins therof and methods of use
1792009011114304/30/09Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1802009009259804/09/09Antibody therapy
1812010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1822010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo